市場概況

External ventricular drainage provides a valuable minimally invasive solution for treating acute hydrocephalus and other conditions necessitating cerebrospinal fluid diversion. As a temporary measure, EVDs are placed directly into the brain’s ventricles to drain excess CSF until stable reabsorption is restored.

Current market forecasts anticipate continued strong growth in EVD systems adoption over the coming years. A projected compound annual growth rate exceeding 7.8 percent reflects intensifying clinical needs as neurosurgery techniques advance and global disease burdens mount. Rates of hydrocephalus especially are considerable, impacting millions worldwide annually.

As a medical emergency, hydrocephalus presents serious risks such as elevated intracranial pressure susceptible to further neurological injury if untreated. Prompt CSF drainage through EVD placement is therefore paramount to stabilize patients for additional shunt or management procedures. Expanding access to care even in underserved regions will be key to making these lifesaving interventions more widely available.

Beyond hydrocephalus specifically, EVDs may also benefit head trauma, aneurysm and tumor resection patients experiencing intraventricular hemorrhage or edema. Their integration into post-surgical critical care pathways improves recovery outcomes. Streamlined multi-lumen catheters simplify simultaneous monitoring and drainage while protecting delicate ventricular ependyma from abrasion or occlusion.

From a technological perspective, biomaterials science continues yielding ever more bioabsorbable and anti-migrational materials lessening device complications. Nanocoatings that prevent clogging and infection could further expand applications to chronic settings. Overall market prospects appear bright as user-friendly EVD design and care delivery optimization enhance the quality and efficiency of complex neurosurgical cases.

市場セグメンテーション

この業界レポートは、世界市場の市場推定と予測を提供します。, 続いてアプリケーションの詳細な分析, patient group, そして地理.
応用: intracerebral brain hemorrhage (ICH), subarachnoid hemorrhage, traumatic brain injury (TBI), その他
Patient group: 小児, アダルト
地理: 北米, ヨーロッパ, アジア太平洋地域, 中東とアフリカ, ラテンアメリカ

Analyzing by application, traumatic brain injury (TBI) accounted for the dominant share of 38.1% of total market revenue in 2022. This segment is poised to chart the fastest expansion over the forecast period as well.

The rising incidence of TBI worldwide is the predominant factor driving acute EVD adoption. Per estimates, over 60 million new cases of TBI arising from falls, accidents and assaults are recorded annually across the globe.

TBI often leads to accumulation of excess cerebrospinal fluid in the brain due to hematomas or edema, heightening intracranial pressure. Acute EVD catheters provide crucial intervention by draining this fluid to stabilize patients. Usage helps mitigate secondary brain injury from elevated pressure, enabling recovery.

Based on geography, North America held the leading 35.6% の市場シェア 2021. Dominance of North America stems from the high prevalence of neurological conditions like hemorrhagic and ischemic strokes, hydrocephalus, tumors requiring EVD intervention.

Established healthcare access and infrastructure also advantage the region, with specialized neuro-critical care units equipped with the latest technology. Reimbursement coverage for emergency neurosurgery procedures further propagates acute EVD placements. The U.S. remains at the epicenter of progress, with advanced new EVD devices receiving FDA approvals to meet evolving clinical needs.

Asia Pacific is forecast to grow at the most rapid clip globally, riding tailwinds like expanding healthcare expenditure, patient pool and neurosurgery infrastructure. Specifically China, Japan and India will present considerable opportunities as investment flows into facilities and equipment modernization.

主要企業と競争環境

The market research report covers the analysis of key stake holders of the global acute EVD market. Some of the leading players profiled in the report include Fuji Systems Corporation, Integra LifeSciences Holdings Corporation, メドトロニック株式会社, Natus Medical Incorporated, Neuromedex GmbH, Sophysa SA, Spiegelberg GmbH & コ. KG, とりわけ. このレポートでは, 市場の競争見通しを理解するために、主要なプレーヤーとその戦略を徹底的に分析します。.

報告書の範囲

To analyze and forecast the market size of the global acute EVD market.
To classify and forecast the global acute EVD market based on application, patient group, 地理.
To identify drivers and challenges for the global acute EVD market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global acute EVD market.
To identify and analyze the profile of leading players operating in the global acute EVD market.

このレポートを選択する理由

Gain a reliable outlook of the global acute EVD market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.